Form 8-K TG THERAPEUTICS, INC. For: Nov 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Roth Positive on TG Therapeutics (TGTX) Following Q3 Results; Expects Strong ASH Showing
November 11, 2014 11:31 AM ESTRoth Capital affirms TG Therapeutics (Nasdaq: TGTX) at Buy with a price target of $25 following Q3 results. TGTX posted Q3 loss of $0.51 per share, versus the firm's estimate looking for a loss of $0.32 per share.
Analyst Joseph Pantginis commented, Over the last 12 months, TG has transformed itself with what we consider to be striking clinical data to a pivotal stage company. The... More
